 |
|
|
| |
Early versus delayed use of sofosbuvir plus peginterferon/ribavirin therapy in fibrosis patients with hepatitis C virus: a cost-effectiveness analysis
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
M. Buti1, R. Domínguez-Hernández2, I. Oyagüez2, M. Rueda3, MA. Casado2
1Hospital Vall' d'Hebron, Barcelona, Spain; 2Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain; 3Gilead Sciences, Madrid, Spain.
|
| |
|
|
|
|
|
